Epidemiologie - France Portal | Health Databases

Home

Catalogue

Catalogue
ARCHIVES

Covid-19

Resources

Lexicon
Legal notices

Useful links

General links
Covid-19 links

Login in to your account

Email address Password

You do not have an account yet ? Sign up !

You have forgotten your password ?

Portail Epidémiologique

ITMO public health Aviesan

Aviesan

Archives

Search with one or more keywords

All records French records only English records only

This page gives you access to all the studies carried out by French researchers, identified on Covid-19.

To view other resources related to Covid-19, click here.

xml

Export to XML

Please choose the format :

pdf

Export to PDF

Which version do you want to export ?

Download full content

Download light content

csv

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection

ARCHIVES : 309 forms

Sorting of results :

Flurec - Recurring influenza virus infections and implications in terms of epidemic recurrences and pandemic risk.

Head : Carrat Fabrice, UMR-S 707 / Epidémiologie des maladies infectieuses et modélisation
De Lamballerie Xavier, UMR-D 190, Emergence des pathologies virales

Version 1

91

Last update : 01/01/2020

ARCHIVE

Flurec - Recurring influenza virus infections and implications in terms of epidemic recurrences and pandemic risk.

Head : Carrat Fabrice, UMR-S 707 / Epidémiologie des maladies infectieuses et modélisation
De Lamballerie Xavier, UMR-D 190, Emergence des pathologies virales

Main objective

To explore cross-protective immunity involving different A/H1N1 viruses (seasonal and pandemic) and the seasonal A/H3N2 virus through data gathered from this study. This study also aims to identify the epidemiological, immunological and virological factors that determine the risk of recurring influenza infections as well as characterise the population's herd immunity and its evolution.

Inclusion criteria

The "influenza" group comprises of patients enrolled after general medical consultation for influenza-like illness during seasonal epidemic. The "non-influenza" group comprises of patients enrolled after general medical consultation during seasonal epidemic for a reason other than influenza, yet that was acute in nature e.g. infectious diarrhoea, minor trauma.

Last update : 01/01/2020

ASSESS - Assessment of Systemic Involvement and Progression for Patients with Primary Sjogren's Syndrome

Head : Gottenberg Jacques-Eric, U1109 Immuno-rhumatologie moléculaire

Version 2

92

Last update : 01/01/2019

ARCHIVE

ASSESS - Assessment of Systemic Involvement and Progression for Patients with Primary Sjogren's Syndrome

Head : Gottenberg Jacques-Eric, U1109 Immuno-rhumatologie moléculaire

Main objective

To prospectively determine for the first time the prevalence and risk factors for systemic complications and lymphoma in primary Sjögren's syndrome.

Inclusion criteria

- Men or women - adults - patients in tertiary centres for autoimmune diseases

Last update : 01/01/2019

ADEOS - Adherence evaluation of osteoporosis treatment

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Version 1

93

Last update : 01/01/2018

ARCHIVE

ADEOS - Adherence evaluation of osteoporosis treatment

Head : Leclerc-Zwirn Christel, Laboratoire GSK

Main objective

Finalize and validate a self-administered instrument developed to evaluate adhesion to the treatment
of postmenopausal osteoporosis

Inclusion criteria

Woman;
Over the age of 50 years;
Patient to whom has been prescribed one of the following osteoporosis treatments in the six months prior to the inclusion starting date:
bisphosphonates, selective estrogen receptor modulators (SERM), or strontium ranelate;
Patient fluent in French and who has the cognitive and functional ability required to complete
the self-questionnaires included in the study on their own;
Informed patient who has given their oral consent to participate in this study

Last update : 01/01/2018

CEPHEUS - Assessment of lipid-lowering treatment in France

Head : Ferrières Jean, Département d'épidémiologie INSERM UMR1027

Version 3

94

Last update : 09/05/2017

ARCHIVE

CEPHEUS - Assessment of lipid-lowering treatment in France

Head : Ferrières Jean, Département d'épidémiologie INSERM UMR1027

Main objective

Determine the proportion of patients on lipid-lowering drugs who reach the LDL-C goals recommended in guidelines.

Inclusion criteria

man or woman - adult - treated with lipid-lowering drugs for at least three months, with no dose adjustment for a minimum of six weeks

Last update : 09/05/2017

ABSINTHE - Observational study of the therapeutic strategy in the management of acute sinusitis in primary care

Head : Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Version 2

95

Last update : 09/05/2017

ARCHIVE

ABSINTHE - Observational study of the therapeutic strategy in the management of acute sinusitis in primary care

Head : Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Main objective

The study objectives were to describe the management of acute sinusitis in real-life conditions of prescription and to evaluate the effectiveness of the initial therapeutic strategy.

Inclusion criteria

Patient consulting for acute sinusitis diagnosed according to criteria of the practitioner; Patient without a previous episode of acute sinusitis during the two months preceding diagnosis; Patient aged 18 years and over; Patient agreeing to participate in the study; Patient not included in a clinical trial (Huriet-Sérusclat); Patient who may be followed for two months; Patient showing no severe active disease (life-threatening in the next three months).

Last update : 09/05/2017

B009 - Follow-up study of patients treated with drotrecogin alfa (activated) (Xigris®) in France

Head : Laboratoire , Eli Lilly France

Version 1

96

Last update : 01/01/2019

ARCHIVE

B009 - Follow-up study of patients treated with drotrecogin alfa (activated) (Xigris®) in France

Head : Laboratoire , Eli Lilly France

Main objective

Primary objective: evaluate 1-month mortality (at 28 days and 31 days) of patients treated with drotrecogin alpha (activated) in intensive care forsevere sepsis and describe causes of death.
Secondary objectives: characteristics of patients and conditions of use.

Inclusion criteria

All adult patients treated with drotrecogin alpha (activated) in France in the course of routine care in intensive care services.

Last update : 01/01/2019

Previous
1
...
10
11
12
13
14
15
16
17
18
19
20
21
22
...
52
Next

Please wait...

ABOUT

Help about your workspace

CATALOG

RESOURCES

USEFUL LINKS

This site complies with the HONcode standard for trustworthy health information:
verify here.

8 rue de la Croix Jarry

75013 Paris

Phone : +33 1 44 23 67 47

portail-epidemiologie@inserm.fr

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

XXX

View Edit Create here